title: A retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutaryl coenzyme A reductase therapy in HIV-infected patients with hyperlipidemia.
abstract: BACKGROUND
  Abnormalities in lipid metabolism are a well-described consequence of human immunodeficiency virus (HIV) infection being treated with highly active antiretroviral therapies (HAART).
  
  
  OBJECTIVE
  The purpose of this study is to evaluate the lipid-lowering efficacy and safety of ezetimibe added to existing hydroxy methylglutaryl coenzyme A reductase (statin) therapy in HIV-infected patients with hyperlipidemia.
  
  
  METHODS
  This is a retrospective study utilizing a comprehensive electronic patient registry to identify all adult HIV-infected patients seen at the Dallas Veterans Affairs (VA) Medical Center during a 4-year period from October 1, 2002 through October 1, 2006.
  
  
  RESULTS
  A total of 26 HIV-infected patients initiated on ezetimibe 10 mg were identified, with 14 adult males meeting strict criteria for inclusion. Median age was 54 years (interquartile range [IQR], 45-59) with a median duration of HIV of 13 years, CD4 count of 513 cells/mm(3) (IQR, 289-736), and 9 of 14 patients had undetectable viral loads at baseline. Initiation of ezetimibe 10 mg resulted in a significant decrease in total cholesterol (TC) from baseline (-12.9%, P = 0.001); low-density lipoprotein cholesterol (LDL-C; -25.7%, P = 0.001); and non-high-density lipoprotein cholesterol (non-HDL-C; -23.9%, P = 0.001). There was also a nonsignificant decrease in triglycerides (15.8%, P = 0.43), and an increase in number of patients achieving National Cholesterol Education Program/Adult Treatment Panel III goal for LDL-C after initiation of ezetimibe (+20.9%, P = 0.125). These improvements occurred without adverse effects or changes in virologic and immunologic control.
  
  
  CONCLUSIONS
  Addition of ezetimibe to existing statin therapy in HIV-infected VA patients treated with HAART significantly reduces TC, LDL-C, and non-HDL-C concentrations without apparent side effects or compromising of virologic control.
authors.affiliation: Texas Tech University Health Sciences Center School of Pharmacy, Dallas/Ft. Worth Regional Campus, 4500 S. Lancaster Road, Building 7, Dallas, TX 75216, USA; North Texas Veterans Affairs Health Care Systems, Dallas, TX 75216, USA.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Chastain
authors.forename: Amy M
authors.initials: AM
authors.lastname: Bain
authors.forename: Krystal L
authors.initials: KL
authors.lastname: Edwards
authors.forename: Roger
authors.initials: R
authors.lastname: Bedimo
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Busti